株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ウイルス性結膜炎パイプライン薬剤市場: 業界分析、パイプラインレビュー、特許分析、2019〜2027年の予測

Viral Conjunctivitis Therapeutics and Pipeline Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027

発行 Transparency Market Research 商品コード 364443
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.97円で換算しております。
Back to Top
ウイルス性結膜炎パイプライン薬剤市場: 業界分析、パイプラインレビュー、特許分析、2019〜2027年の予測 Viral Conjunctivitis Therapeutics and Pipeline Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027
出版日: 2019年07月17日発行予定 ページ情報: 英文
概要

ウイルス性結膜炎パイプライン薬剤市場は、英国、米国、ドイツ、オーストラリア、日本、ブラジルが主要市場となっており、継続中の治験を考慮すると、米国が今後数年間、市場を独占するとみられています。米国のウイルス性結膜炎パイプライン薬剤市場は、2020〜2023年にかけCAGR46.5%で拡大すると予測されています。

当レポートでは、世界のウイルス性結膜炎パイプライン薬剤市場について調査し、市場の現況と将来見通し、装置別、地域別動向、および参入企業のプロファイルをまとめています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 業界分析

  • イントロダクション
    • 兆候と症状
    • 診断
    • 管理
  • 市場動向
    • 市場促進因子
      • 大きなアンメットニーズ
      • 強固なパイプライン
    • 阻害因子
      • 低い診断率
      • 自己制限
    • 機会
      • 厳しい研究開発活動へおn投資
    • 商品化活動の強化
  • 疫学環境
  • パイプライン薬剤の特許分析

第4章 パイプライン薬剤別市場

  • イントロダクション
  • FST-100
  • APD-209
  • 早期前臨床試験

第5章 市場セグメンテーション:国別

  • イントロダクション
  • 米国
  • 英国
  • ドイツ
  • オーストラリア
  • 日本
  • ブラジル

第6章 提言

第7章 企業プロファイル

  • Adenovir Pharma AB
  • Allergan plc
  • NanoViricides, Inc.
  • Shire plc
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • Panoptes Pharma GES.M.B.H.
  • NicOx S.A.

図表

図表

List of Figures

  • FIG. 1: Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023 (E)
  • FIG. 2: Industry Analysis: Viral Conjunctivitis Pipeline Drugs Market
  • FIG. 3: Viral Conjunctivitis: Signs and Symptoms
  • FIG. 4: Market Revenue of FST-100, (US$ Mn), 2020-2023
  • FIG. 5: Market Revenue of APD-209, (US$ Mn), 2021-2023
  • FIG. 6: U.S. Viral Conjunctivitis Pipeline Drugs Market Revenue, (US$ Mn), 2020-2023
  • FIG. 7: U.K. Market Revenue, (US$ Mn), 2021-2023
  • FIG. 8: Germany Market Revenue, (US$ Mn), 2021-2023
  • FIG. 9: Australia Market Revenue, (US$ Mn), 2022-2023
  • FIG. 10: Japan Market Revenue, (US$ Mn), 2022-2023
  • FIG. 11: Brazil Market Revenue, (US$ Mn), 2020-2023
  • FIG. 12: Allergan Financial Overview: (US$ Mn), 2012-2014
  • FIG. 13: NanoViricides, Inc., Financial Overview: (US$ Mn), 2013-2015
  • FIG. 14: Shire plc, Financial Overview: (US$ Mn), 2013-2015
  • FIG. 15: NovaBay Pharmaceuticals, Inc., Financial Overview: (US$ Mn), 2013-2015
  • FIG. 16: Novartis AG, Financial Overview: (US$ Mn), 2013-2015
  • FIG. 17: NicOx S.A., Financial Overview: (US$ Mn), 2013-2015

List of Tables

  • TABLE 1: Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot
  • TABLE 2: Viral Conjunctivitis: Management
  • TABLE 3: Epidemiology
  • TABLE 4: Patent Analysis of Pipeline Drugs
  • TABLE 5: Viral Conjunctivitis Pipeline Drugs Market Revenue, by Pipeline Drug, (US$ Mn), Expected Launch-2023
  • TABLE 6: Early Stage Preclinical Trials
  • TABLE 7: Viral Conjunctivitis Pipeline Drugs Market Revenue, by Country, (US$ Mn), 2020-2023
目次

Viral conjunctivitis therapeutics is undergoing a transitional phase. Currently, there is no drug available for the treatment of viral conjunctivitis. However, the presence of a robust pipeline indicates towards a thriving future. The global market for viral conjunctivitis pipeline drugs is likely to exhibit a thumping CAGR of 69.60% between 2020 and 2023 and reach an opportunity worth US$462.4 mn by the end of the forecast period.

The increasing investments from ophthalmic drug manufacturers for the development of efficient treatment for viral conjunctivitis, coupled with the increasing awareness among people and augmenting expenditure on healthcare, are accelerating the growth rate of this market significantly.

On the other hand, lower diagnosis rate of viral conjunctivitis is decreasing the patient pool for the treatment, causing major hindrance in the market's growth.

Pipeline Drugs in U.S. Gain Momentum from Promising Results of Ongoing Clinical Trials

The U.K., the U.S., Germany, Australia, Japan, and Brazil are the key regional markets for viral conjunctivitis pipeline drugs. Considering the ongoing clinical trials, the U.S. is likely to occupy the leading position among these in the coming years. The major factors driving the growth in this market are promising results of the ongoing clinical trials, the increasing awareness regarding eye care among patients and medical professionals, the high cost of the drugs, and the availability of viral conjunctivitis diagnostic tests.

The U.S. market for viral conjunctivitis pipeline drugs is projected to report a CAGR of 46.50% during the period from 2020 to 2023.

APD-209 to Exceed FST-100 by 2023

APD-209 and FST-100 are the main viral conjunctivitis drugs in the pipeline. Among the two, FST-100 is projected to hold the largest share in the market by 2020. Foresight Biotherapeutics Inc. initiated the development of FST-100; however, the company was acquired by Shire Plc. in the midway. In May 2014, the drug completed its phase II clinical trial successfully and is expected to enter the phase III of clinical trials in 2016.

Presently, the APD-209 is witnessing moderate rise; however, in the coming years, it will report a higher demand than FST-100. The drug, being developed by Adenovir Pharma AB, is in its second phase of clinical trial. It is likely to enter the third phase by mid-2016.

The market for FST-100 is projected to rise at a CAGR of 27.40% between 2020 and 2023 while the APD-209 market is likely to report a CAGR of 55.0% during the same period.

Leading Players Focus on Research Activities Thanks to Escalating Demand for Targeted Drugs for Viral Conjunctivitis

On the forefront of the global viral conjunctivitis pipeline drugs market are Panoptes Pharma GES.M.B.H., Shire Plc., Allergan Plc, Novartis AG, NovaBay Pharmaceuticals Inc., Adenovir Pharma AB, NicOx S.A., and NanoViricides Inc. As the demand for targeted drugs for viral conjunctivitis is rising, leading enterprises are focusing aggressively on research activities for the development of efficient treatments as well as diagnostic tests for viral conjunctivitis. New entrants in this market are recommended to enhance their distribution networks through strategic partnerships and alliances with local distributors.

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Research Methodology
  • 1.3. Assumptions
  • 1.4. Market Segmentation

2. Executive Summary

  • 2.1. Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023
  • 2.2. Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot

3. Viral Conjunctivitis Pipeline Drugs Market - Industry Analysis

  • 3.1. Introduction
    • 3.1.1. Sign and Symptoms
    • 3.1.2. Diagnosis
    • 3.1.3. Management
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers
      • 3.2.1.1. Large Unmet Needs
      • 3.2.1.2. Strong Pipeline
    • 3.2.2. Restraints
      • 3.2.2.1. Low diagnosis rate
      • 3.2.2.2. Self-Limiting Condition
    • 3.2.3. Opportunity
      • 3.2.3.1. Investment in Rigorous R&D Activities
      • 3.2.3.2. Strengthen Commercialization Activities
  • 3.3. Epidemiology
  • 3.4. Patent Analysis of Pipeline Drugs

4. Market Segmentation - By Pipeline Drug

  • 4.1. Introduction
  • 4.2. Market Revenue of FST-100 (SHP-640), 2020-2023, (US$ Mn)
  • 4.3. Market Revenue of APD-209, 2021-2023, (US$ Mn)
  • 4.4. Early Stage Preclinical Trials (Tabular Form)

5. Market Segmentation - By Country

  • 5.1. Introduction
  • 5.2. U.S. Viral Conjunctivitis Pipeline Drugs Market, 2020-2023, (US$ Mn)
  • 5.3. U.K Viral Conjunctivitis Pipeline Drugs Market, 2021-2023, (US$ Mn)
  • 5.4. Germany Viral Conjunctivitis Pipeline Drugs Market, 2021-2023, (US$ Mn)
  • 5.5. Australia Viral Conjunctivitis Pipeline Drugs Market, 2022-2023, (US$ Mn)
  • 5.6. Japan Viral Conjunctivitis Pipeline Drugs Market, 2022-2023, (US$ Mn)
  • 5.7. Brazil Viral Conjunctivitis Pipeline Drugs Market, 2020-2023, (US$ Mn)

6. Recommendations

7. Company Profiles

  • 7.1. Adenovir Pharma AB
  • 7.2. Allergan plc
  • 7.3. NanoViricides, Inc.
  • 7.4. Shire plc
  • 7.5. NovaBay Pharmaceuticals, Inc.
  • 7.6. Novartis AG
  • 7.7. Panoptes Pharma GES.M.B.H.
  • 7.8. NicOx S.A.
Back to Top